Maintenance of neovascularization at the implantation site of an artificial device by bFGF and endothelial cell transplant

Atsushi Miki, Jorge D. Rivas-Carrillo, Nalu Navarro-Alvarez, Alejandro Soto-Gutierrez, Yong Chen, Kimiaki Tanaka, Michiki Narushima, Yasuhiko Tabata, Teru Okitsu, Hirofumi Noguchi, Shinichi Matsumoto, Noriaki Tanaka, Naoya Kobayashi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Development of a subcutaneously implantable bioartificial pancreas (BAP) with immunoisolatory function could have a great impact on the treatment of diabetes mellitus. We have developed an implantable BAP device with an ethylene vinyl alcohol (EVAL) membrane. In the present study, we used basic fibroblast growth factors (bFGF), which was incorporated in a carrier for sustained release, in order to induce neovascularization when the device was implanted subcutaneously. To maintain the vasculature thus formed, a cell infusion port was attached to the BAP device, through which the device was filled with human liver vascular endothelial cell line TMNK-1, and the vasculature could be adequately maintained. Mice were divided into the following three groups. In group 1, a bFGF-free BAP device was implanted subcutaneously. In group 2, a sustained-release bFGF-impregnated BAP device was implanted. In group 3, a sustained-release bFGF-impregnated BAP device was implanted, and 3 × 106 TMNK-1 cells were infused into the implanted device every week. Neovascularization induced in the subcutaneous tissue around the implanted BAP device was macroscopically examined and histologically evaluated. In addition, the tissue blood flow was measured using a laser blood flow meter. In mice in group 3, neovascularization was significantly induced and maintained until week 8 postimplantation. It was confirmed by scanning electron microscopy that infused TMNK-1 cells adhered to the inner polyethylene surface of the device. It was demonstrated that the use of bFGF and vascular endothelial TMNK-1 cells induced and maintained adequate vasculature and tissue blood flow surrounding the implantable bag-type BAP device. We believe that the present study will contribute to BAP development for the treatment of diabetes.

Original languageEnglish (US)
Pages (from-to)893-901
Number of pages9
JournalCell Transplantation
Volume15
Issue number10
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Transplants
Endothelial cells
Fibroblast Growth Factor 2
Fibroblasts
Endothelial Cells
Maintenance
Pancreas
Equipment and Supplies
Blood
Tissue
Medical problems
Liver
Polyethylenes
Ethylene
Alcohols
Intercellular Signaling Peptides and Proteins
Membranes
Scanning electron microscopy
Lasers
Subcutaneous Tissue

Keywords

  • Basic fibroblast growth factor
  • Bioartificial pancreas
  • Human vascular endothelial cells
  • Neovascularization

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation

Cite this

Miki, A., Rivas-Carrillo, J. D., Navarro-Alvarez, N., Soto-Gutierrez, A., Chen, Y., Tanaka, K., ... Kobayashi, N. (2006). Maintenance of neovascularization at the implantation site of an artificial device by bFGF and endothelial cell transplant. Cell Transplantation, 15(10), 893-901. https://doi.org/10.3727/000000006783981378

Maintenance of neovascularization at the implantation site of an artificial device by bFGF and endothelial cell transplant. / Miki, Atsushi; Rivas-Carrillo, Jorge D.; Navarro-Alvarez, Nalu; Soto-Gutierrez, Alejandro; Chen, Yong; Tanaka, Kimiaki; Narushima, Michiki; Tabata, Yasuhiko; Okitsu, Teru; Noguchi, Hirofumi; Matsumoto, Shinichi; Tanaka, Noriaki; Kobayashi, Naoya.

In: Cell Transplantation, Vol. 15, No. 10, 2006, p. 893-901.

Research output: Contribution to journalArticle

Miki, A, Rivas-Carrillo, JD, Navarro-Alvarez, N, Soto-Gutierrez, A, Chen, Y, Tanaka, K, Narushima, M, Tabata, Y, Okitsu, T, Noguchi, H, Matsumoto, S, Tanaka, N & Kobayashi, N 2006, 'Maintenance of neovascularization at the implantation site of an artificial device by bFGF and endothelial cell transplant', Cell Transplantation, vol. 15, no. 10, pp. 893-901. https://doi.org/10.3727/000000006783981378
Miki, Atsushi ; Rivas-Carrillo, Jorge D. ; Navarro-Alvarez, Nalu ; Soto-Gutierrez, Alejandro ; Chen, Yong ; Tanaka, Kimiaki ; Narushima, Michiki ; Tabata, Yasuhiko ; Okitsu, Teru ; Noguchi, Hirofumi ; Matsumoto, Shinichi ; Tanaka, Noriaki ; Kobayashi, Naoya. / Maintenance of neovascularization at the implantation site of an artificial device by bFGF and endothelial cell transplant. In: Cell Transplantation. 2006 ; Vol. 15, No. 10. pp. 893-901.
@article{057fe954ffa34346ae193222f3d854ed,
title = "Maintenance of neovascularization at the implantation site of an artificial device by bFGF and endothelial cell transplant",
abstract = "Development of a subcutaneously implantable bioartificial pancreas (BAP) with immunoisolatory function could have a great impact on the treatment of diabetes mellitus. We have developed an implantable BAP device with an ethylene vinyl alcohol (EVAL) membrane. In the present study, we used basic fibroblast growth factors (bFGF), which was incorporated in a carrier for sustained release, in order to induce neovascularization when the device was implanted subcutaneously. To maintain the vasculature thus formed, a cell infusion port was attached to the BAP device, through which the device was filled with human liver vascular endothelial cell line TMNK-1, and the vasculature could be adequately maintained. Mice were divided into the following three groups. In group 1, a bFGF-free BAP device was implanted subcutaneously. In group 2, a sustained-release bFGF-impregnated BAP device was implanted. In group 3, a sustained-release bFGF-impregnated BAP device was implanted, and 3 × 106 TMNK-1 cells were infused into the implanted device every week. Neovascularization induced in the subcutaneous tissue around the implanted BAP device was macroscopically examined and histologically evaluated. In addition, the tissue blood flow was measured using a laser blood flow meter. In mice in group 3, neovascularization was significantly induced and maintained until week 8 postimplantation. It was confirmed by scanning electron microscopy that infused TMNK-1 cells adhered to the inner polyethylene surface of the device. It was demonstrated that the use of bFGF and vascular endothelial TMNK-1 cells induced and maintained adequate vasculature and tissue blood flow surrounding the implantable bag-type BAP device. We believe that the present study will contribute to BAP development for the treatment of diabetes.",
keywords = "Basic fibroblast growth factor, Bioartificial pancreas, Human vascular endothelial cells, Neovascularization",
author = "Atsushi Miki and Rivas-Carrillo, {Jorge D.} and Nalu Navarro-Alvarez and Alejandro Soto-Gutierrez and Yong Chen and Kimiaki Tanaka and Michiki Narushima and Yasuhiko Tabata and Teru Okitsu and Hirofumi Noguchi and Shinichi Matsumoto and Noriaki Tanaka and Naoya Kobayashi",
year = "2006",
doi = "10.3727/000000006783981378",
language = "English (US)",
volume = "15",
pages = "893--901",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "10",

}

TY - JOUR

T1 - Maintenance of neovascularization at the implantation site of an artificial device by bFGF and endothelial cell transplant

AU - Miki, Atsushi

AU - Rivas-Carrillo, Jorge D.

AU - Navarro-Alvarez, Nalu

AU - Soto-Gutierrez, Alejandro

AU - Chen, Yong

AU - Tanaka, Kimiaki

AU - Narushima, Michiki

AU - Tabata, Yasuhiko

AU - Okitsu, Teru

AU - Noguchi, Hirofumi

AU - Matsumoto, Shinichi

AU - Tanaka, Noriaki

AU - Kobayashi, Naoya

PY - 2006

Y1 - 2006

N2 - Development of a subcutaneously implantable bioartificial pancreas (BAP) with immunoisolatory function could have a great impact on the treatment of diabetes mellitus. We have developed an implantable BAP device with an ethylene vinyl alcohol (EVAL) membrane. In the present study, we used basic fibroblast growth factors (bFGF), which was incorporated in a carrier for sustained release, in order to induce neovascularization when the device was implanted subcutaneously. To maintain the vasculature thus formed, a cell infusion port was attached to the BAP device, through which the device was filled with human liver vascular endothelial cell line TMNK-1, and the vasculature could be adequately maintained. Mice were divided into the following three groups. In group 1, a bFGF-free BAP device was implanted subcutaneously. In group 2, a sustained-release bFGF-impregnated BAP device was implanted. In group 3, a sustained-release bFGF-impregnated BAP device was implanted, and 3 × 106 TMNK-1 cells were infused into the implanted device every week. Neovascularization induced in the subcutaneous tissue around the implanted BAP device was macroscopically examined and histologically evaluated. In addition, the tissue blood flow was measured using a laser blood flow meter. In mice in group 3, neovascularization was significantly induced and maintained until week 8 postimplantation. It was confirmed by scanning electron microscopy that infused TMNK-1 cells adhered to the inner polyethylene surface of the device. It was demonstrated that the use of bFGF and vascular endothelial TMNK-1 cells induced and maintained adequate vasculature and tissue blood flow surrounding the implantable bag-type BAP device. We believe that the present study will contribute to BAP development for the treatment of diabetes.

AB - Development of a subcutaneously implantable bioartificial pancreas (BAP) with immunoisolatory function could have a great impact on the treatment of diabetes mellitus. We have developed an implantable BAP device with an ethylene vinyl alcohol (EVAL) membrane. In the present study, we used basic fibroblast growth factors (bFGF), which was incorporated in a carrier for sustained release, in order to induce neovascularization when the device was implanted subcutaneously. To maintain the vasculature thus formed, a cell infusion port was attached to the BAP device, through which the device was filled with human liver vascular endothelial cell line TMNK-1, and the vasculature could be adequately maintained. Mice were divided into the following three groups. In group 1, a bFGF-free BAP device was implanted subcutaneously. In group 2, a sustained-release bFGF-impregnated BAP device was implanted. In group 3, a sustained-release bFGF-impregnated BAP device was implanted, and 3 × 106 TMNK-1 cells were infused into the implanted device every week. Neovascularization induced in the subcutaneous tissue around the implanted BAP device was macroscopically examined and histologically evaluated. In addition, the tissue blood flow was measured using a laser blood flow meter. In mice in group 3, neovascularization was significantly induced and maintained until week 8 postimplantation. It was confirmed by scanning electron microscopy that infused TMNK-1 cells adhered to the inner polyethylene surface of the device. It was demonstrated that the use of bFGF and vascular endothelial TMNK-1 cells induced and maintained adequate vasculature and tissue blood flow surrounding the implantable bag-type BAP device. We believe that the present study will contribute to BAP development for the treatment of diabetes.

KW - Basic fibroblast growth factor

KW - Bioartificial pancreas

KW - Human vascular endothelial cells

KW - Neovascularization

UR - http://www.scopus.com/inward/record.url?scp=33846581501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846581501&partnerID=8YFLogxK

U2 - 10.3727/000000006783981378

DO - 10.3727/000000006783981378

M3 - Article

VL - 15

SP - 893

EP - 901

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 10

ER -